Novartis — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2024· 14 events
Novartis is committed to using 100% renewable electricity across operations by 2025 following RE100 principles. In 2024, 96% of purchased electricity was renewable (up from 92% in 2023). Uses 100% renewable electricity in North America and Europe through virtual power purchase agreements (VPPAs). Participates in Energize, an industry initiative led with Schneider Electric to facilitate market access for renewable electricity procurement among suppliers.
sustainability_report p.25
Novartis discloses Scope 3 emissions categories considered relevant in 2024 including newly disclosed categories. 2023 and 2022 data has been updated accordingly.
sustainability_report p.61
Conducted nature assessment for own operations and upstream supply chain aligned with TNFD LEAP approach. Plan to implement sustainable sourcing program starting with pilot in 2025.
sustainability_report p.33
Reducing energy demand through efficiency initiatives and process innovations, implementing green technologies across operating sites. Transitioning fleet to electric vehicles by 2030 in line with EV100 commitment. Deployed USD 40 million capital expenditure on environmental projects in 2024. Scope 1+2 emissions reduced 20% YoY and 71% from 2016 baseline.
sustainability_report p.25
Transportation Scope 3 emissions managed across upstream (cat 4: 166 ktCO2e) and downstream (cat 9: 111 ktCO2e). Cold-chain and radioligand therapy delivery require quick transport given short isotope half-lives. Investing in regional RLT manufacturing facilities (Indianapolis, Carlsbad CA, Italy, Slovenia) to shorten supply chains.
sustainability_report p.21
Reduce amount of waste sent for disposal by 30% by 2030 from a 2022 baseline. 2025 target (50% reduction from 2016) already achieved.
sustainability_report p.31
2023 and 2022 water usage performance indicators updated to include Novartis entity Abadia Retuerta and revised estimate from the Sandoz/Novartis split for manufacturing operations in Austria.
sustainability_report p.61
95% of emissions are Scope 3 generated outside operations. Embedded environmental sustainability into core procurement processes; contracts including environmental sustainability criteria now cover 76% of Scope 3 emissions (up 19 ppts YoY). Onboarded suppliers covering more than two-thirds of Scope 3 emissions. Introduced Environmental Sustainability Supplier Playbook shared with 1000+ suppliers. Participating in WBCSD Partnership for Carbon Transparency.
sustainability_report p.28
By end of 2024, eliminated 100% of PVC in secondary and tertiary packaging at 24 manufacturing sites handling final product packaging (vs 2016). Established baseline for reducing plastics in packaging and devices. Improved process efficiencies and used more recycled plastics and reusable shipping boxes. Continuing to remove single-use plastics in workplaces.
sustainability_report p.31
Near-term: reduce Scope 1+2 by 90% and Scope 3 by 42% by 2030 from 2022 base year. Long-term: reduce emissions across all scopes by 90% by 2040 (net zero). 2025 target: carbon neutral in own operations from energy.
sustainability_report p.26
Strategic acquisitions to increase technological capacity and broaden pipeline, including MorphoSys (added pelabresib) and Mariana Oncology.
sustainability_report p.48
Successfully completed first ISO 9001:2015 surveillance audit in 2024 without any nonconformities.
sustainability_report p.39
Systematically integrate life-cycle assessment (LCA) methods in R&D pipeline to calculate and improve environmental impact of products. Implemented measures to reduce waste and emissions from clinical trials. Obtained My Green Lab certification for 96% of laboratories in technical R&D.
sustainability_report p.26
While prioritizing absolute emission reductions, Novartis plans to neutralize any Scope 1 and 2 emissions from energy that remain in 2025 using a mix of high-quality biomethane certificates and nature-based carbon removal solutions. For 2040 net-zero targets, will align with SBTi Corporate Net-Zero standard (max 10% of Scope 1, 2, 3 emissions via offsets). Stress-tested against BNEF forecasts including BECCS and direct air capture.
sustainability_report p.26
2023· 1 event
Sandoz, the former generics and biosimilars business, was spun off in 2023. The 2016 baseline for environmental targets has been restated to remove Sandoz. Novartis is now a pure-play medicines company.
sustainability_report p.3